Cochrane · systematic review · CD015374
Chemotherapy for second‐stage human African trypanosomiasis: drugs in use
Lutje, V, Probyn, K, Seixas, J, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 25%Low 1 · 25%Moderate 2 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table 1
Population: ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC > 20 cells/μL or trypanosomes in CSF)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | RR 2.22 [0.49, 10.11] | 1 study · 394 participants | Low Downgraded: risk of bias, imprecision |
Relapsec | RD 0.05 [0.02, 0.08] | 1 study · 394 participants | Moderate Downgraded: risk of bias, imprecision |
Serious adverse events | RR 1.17 [0.64, 2.17] | 1 study · 394 participants | Very low Downgraded: imprecision |
Adverse events | RR 1.01 [0.95, 1.06] | 1 study · 394 participants | Moderate Downgraded: risk of bias |